Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 320
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed hepatocellular carcinoma.
- •High expression of Notch1 in tumor tissues.
排除标准
- •no pathological evidence of HCC
研究组 & 干预措施
TACE
iodized oil (5ml) + Pirarubicin (20mg)
干预措施: TACE (Procedure)
Rg3
20mg, BID, maintained though Month 12
干预措施: Rg3 (Drug)
TACE + Rg3
the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE.
干预措施: TACE + Rg3 (Other)
Control
standard liver protective therapy
干预措施: protective therapy (Procedure)
结局指标
主要结局
Overall Survival
时间窗: 3 years
Time to progression
时间窗: 3 years
次要结局
未报告次要终点
研究者
ShenFeng
vice president of the Eastern Hepatobiliary Surgery Hospital
Eastern Hepatobiliary Surgery Hospital